Day: July 17, 2025

ENCINO, Calif., July 17, 2025 (GLOBE NEWSWIRE) — NETSOL Technologies, Inc. (Nasdaq: NTWK), a leader in AI-powered solutions and services enabling OEMs, dealerships and financial institutions to sell, finance and lease assets, has announced the successful go-live of its Transcend Finance platform for a leading Chinese leasing company, marking the customer’s official launch of operations in the Indonesian market. The customer, known for offering a wide range of leasing solutions across sectors including equipment leasing, asset financing and commercial leasing, has deployed NETSOL’s Transcend Finance for its retail operations, comprising Omni Point of Sale (Omni POS) and Contract Management System (CMS), alongside a customized funding system designed to support their unique operational needs in Indonesia. This go-live marks...

VANCOUVER, British Columbia, July 17, 2025 (GLOBE NEWSWIRE) — VERSES AI Inc. (CBOE: VERS) (OTCQB: VRSSD) (“VERSES” or the “Company”), a cognitive computing company specializing in next-generation agentic software systems, has been recognized by Gartner as a Sample Vendor in the Hype Cycle™ for Artificial Intelligence, 2025. Gartner Hype Cycles provide a graphic representation of the maturity and adoption of technologies and applications, and how they are potentially relevant to solving real business problems and exploiting new opportunities. Forbes says that the Gartner hype cycle is “a product of the famed consulting and reporting firm Gartner, [which] takes individual innovations and puts them on a graph with specific staging, according to anticipated adoption models.” VERSES was named as a Sample Vendor...

ZURICH, July 17, 2025 (GLOBE NEWSWIRE) — VERAXA Biotech AG (“VERAXA” or the “Company”), an emerging leader in designing novel cancer therapies, and Voyager Acquisition Corp.,  a Cayman Islands exempted company and special purpose acquisition company targeting the healthcare sector (NASDAQ:VACH, “Voyager” or the “SPAC”), announced today the filing of a registration statement on Form F-4 (the “Registration Statement”), which includes a preliminary proxy statement, with the U.S. Securities and Exchange Commission (“SEC”) in regards to the proposed Business Combination Agreement announced April 23, 2025. “We are excited to share this pivotal milestone in VERAXA’s journey toward becoming a public company,” commented Christoph Antz, Ph.D., CEO and Co-Founder of VERAXA. “The filing of our Registration Statement marks...

SEATTLE, July 17, 2025 (GLOBE NEWSWIRE) — via IBN — Fifty1 AI Labs, LLC, an innovative subsidiary of Fifty 1 Labs, Inc. (OTC: FITY), is thrilled to announce a strategic partnership with an intent to acquire BioSpark AI Technologies Inc., a Vancouver-based pioneer in advanced AI and large language model (LLM) technologies. Revealed today, this alliance is set to transform drug repurposing by leveraging cutting-edge AI to unlock transformative therapeutic insights from vast volumes of medical literature, advancing functional medicine and preventative care. Unleashing Hidden Insights with AI-Powered Precision This collaboration integrates BioSpark’s proprietary AI and LLM platform with Fifty1 AI Labs’ advanced predictive modeling to explore and organize extensive case-based medical literature. BioSpark’s system...

Company announces rebranded Oceanside, California, commercial retail location opening August 15, 2025 BREA, Calif., July 17, 2025 (GLOBE NEWSWIRE) — via IBN — Mullen Automotive Inc. (NASDAQ: MULN) (“Mullen” or the “Company”), an emerging electric vehicle (“EV”) manufacturer, announces today that in connection with the Company’s plan to change its name to Bollinger Innovations, Inc., NASDAQ recently approved a new stock symbol — BINI. The effective date for the change of the Company’s name and stock symbol is yet to be determined. The Company also announces the rebranding of its Oceanside, California, Commercial Vehicle Center to Bollinger Innovations, Inc. This strategic location, based right off of Interstate 5 in the Southern California gateway city of Oceanside, is situated on the northern tip of San Diego County and just...

LOS ANGELES, July 17, 2025 (GLOBE NEWSWIRE) — Xos, Inc. (NASDAQ: XOS), a leading electric truck manufacturer and fleet services provider, announced it is scheduling the release of its second quarter 2025 operating results on Wednesday, August 13, 2025 after the close of the U.S. financial markets. Management will host a conference call to discuss these financial results at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time that same day. Conference Call and Webcast DetailsDate / Time: Wednesday, August 13, 2025, at 4:30 p.m. ET / 1:30 p.m. PTWebcast https://viavid.webcasts.com/starthere.jsp?ei=1728046&tp_key=89d39ba62cU.S. Toll-Free Dial In :  1-833-816-1411International Dial In :  1-412-317-0507   To access the call by phone, please dial in to one of the above numbers approximately ten minutes before the start...

Dr. Zuraw led clinical development of telitacicept across MG, Sjögren’s, SLE, and RA at RemeGen, resulting in multiple regulatory approvals in China; brings deep U.S. and global development experience to support Vor Bio’s new development focus and execution of late-stage programsCAMBRIDGE, Mass., July 17, 2025 (GLOBE NEWSWIRE) — Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of Qing Zuraw, M.D., M.P.H., M.B.A., as Chief Development Officer, effective immediately. Dr. Zuraw joins Vor Bio with over 25 years of experience leading complex global and U.S. clinical development programs across autoimmune, inflammatory, and immunologic diseases. Most recently, she served as Chief Development Officer and Head of Global Clinical Development...

NEW YORK, July 17, 2025 (GLOBE NEWSWIRE) — Inspired Entertainment, Inc. (“Inspired” or the “Company”) (NASDAQ: INSE), a leading B2B provider of gaming content, technology, hardware, and services, is pleased to announce the expansion of its long-term partnership with William Hill, the iconic sports betting and gaming brand with over 1,300 betting shops across the United Kingdom, and a principal brand within evoke plc (LSE: EVOK). As part of the contract extension, Inspired will deliver a comprehensive upgrade to William Hill’s Virtual Sports offering across its UK retail estate. This rollout includes the integration of all-new and upgraded events into William Hill’s broadcast networks, significantly enhancing the customer experience for both horse and greyhound racing. Additionally, a new third channel dedicated entirely to Virtual...

Self-service portal empowers restaurant partners with real-time insights and streamlined deal management capabilities New tiered subscription model creates additional revenue opportunities while enhancing value proposition for Restaurant.com’s 184,000+ restaurant partners SCHAUMBURG, IL, July 17, 2025 (GLOBE NEWSWIRE) — Giftify, Inc. (NASDAQ: GIFT) (the “Company”), the owner and operator of CardCash.com and Restaurant.com, and a leader in the incentives and rewards industry, today announced the launch of Restaurant.com’s new Restaurant Management Center (RMC), a comprehensive self-service portal that transforms how restaurant partners manage their presence on the nation’s largest restaurant-focused digital deals platform. Key Highlights of the Restaurant Management Center LaunchModern, intuitive...

– Announces Completion of Phase 1 Study of Elraglusib in Pediatric Patients – Prolonged and Durable Complete Responses (CRs) Observed in Two of Ten Refractory Ewing Sarcoma Patients – Two Additional Patients Had Durable Stable Disease in Notoriously Difficult-to-Treat Cancer – Confirmed Partial Response (PR) in a patient with a desmoplastic small-round-cell tumor (DSRCT) – Company Initiating Planning of Phase 2 Trial of Elraglusib in Children, Adolescents, and Adults with Refractory/Resistant Ewing Sarcoma CHICAGO and FORT WORTH, Texas, July 17, 2025 (GLOBE NEWSWIRE) — Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of...